Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 30-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy in Dyslipidemic Subjects With Stage 3 Chronic Kidney Disease

NCT00680017 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00680017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00680017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 30-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy in Dyslipidemic Subjects With Stage 3 Chronic Kidney Disease
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2008
Completion date
April 30, 2011
Enrollment
280 (actual)
Sites
114

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemia, kidney disease